From Russia (with love?) [RSABE / ABEL]

posted by PharmCat  – Russia, 2019-12-04 16:16 (1768 d 19:39 ago) – Posting: # 20924
Views: 7,620

Hello Helmut!

IMHO, main points:

1. Basic words. Review article.
2. ABEL/RSABE - all have TIE inflation.
3. Biggest inflation when CVintra = 25—30%.
4. EMA aproach better than FDA.

Conclusion:

When you are planning bioequivalence trial better look at EMA guidelines, rather than FDA. We know that all approaches have TIE inflation.

I think this is primarily a message to regulatory experts.

Complete thread:

UA Flag
Activity
 Admin contact
23,247 posts in 4,885 threads, 1,652 registered users;
69 visitors (0 registered, 69 guests [including 10 identified bots]).
Forum time: 12:55 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5